Doctor Explains GLP 1 Blindness Risk (Should You Be Worried?)

If you're taking a GLP-1 medication, or

you're thinking about starting one of

these puppies, you probably have heard,

how could you not, something about

blindness. I mean, that's a freaking

big, massive deal. You don't just ignore

that. Oh, I'm not going to worry about

blindness, blah blah blah blah blah. No,

it's going to jolt and impinge on you.

The sad reality of what you're seeing

out there is far from the real data. And

so, that's what I want to break down in

this video is sift the truth from the

BS. And more importantly, I'm going to

teach you how to minimize the real risk,

in addition to just giving you the

actual understanding of what the real

risk is. Because there's a lot of

misinformation out there, and I want to

help clear the air. I'm Dr. Jones, D.C.,

and I've lost 100 lbs myself. I've

coached thousands of patients through

this therapy. Now, I'm not an

ophthalmologist, and I don't write your

prescriptions. But my job though is to

translate what your eye doctor and your

prescribers aren't explaining to each

other or to you, probably, for that

matter. And over the next couple

minutes, I'm going to separate real risk

from the fear-mongering stuff that's

happening. And boy, oh boy, is there a

lot of fear-mongering. So, you'll

understand whether you're one of the

actual people who needs to worry, or one

of the people who can just breathe and

continue using your GLP-1s and do your

thing. Okay, so before we talk numbers

though, you have to understand what

you're actually afraid of. Because most

of what people are calling GLP-1

blindness online isn't what's in the

data. So, the condition being studied is

called NAION, or non-arteritic ischemic

optic neuropathy. Basically, it's a

stroke of the nerve that feeds your

eyeball. The optic nerve is the cable

that connects your brain to your eyes.

Thousands of tiny little fibers bundled

together running through a narrow tunnel

in your skull. In some people, that

tunnel is a little smaller than average.

The cable is a little more crowded. Eye

doctors call this the disc at risk

anatomy. And it's something that you

were born with, or you aren't. And

here's why this matters, because when

blood flow to that nerve gets briefly

compromised, and various factors can

contribute to that, the nerve, it

swells. And in a crowded tunnel, there's

nowhere for it to swell, which can

create a compartment-like effect that

ultimately damages the nerve. And much

of the vision in that eye is often

permanently lost. That's what

non-arteritic ischemic optic neuropathy

is. And I want to be really clear about

what it's not, because a lot of you

watching have been noticing some kind of

vision change on these medications, and

you're assuming the worst. Blurry vision

that comes and goes on GLP-1s is often

blood sugar fluctuation affecting the

lens of your eye, and it typically

resolves as glucose stabilizes. Dry,

irritated eyes from being more

dehydrated than usual. That's

dehydration. Distance vision getting

slightly worse over months. That's aging

or something called refractive change.

None of these things are NAION. This

condition is sudden, and it often

happens overnight. People wake up with

it in one eye, one sector of the visual

field, often with lasting loss. It is a

specific mechanical event in a specific

anatomy that most people aren't carrying

the setup for. And here's the part that

comes back later. Your eye doctor can

look at the back of your eye and tell

you if you have a disc-at-risk setup.

Which camp you're in is going to matter

for everything that's coming next. And

by the way, if you're sitting here

realizing that you don't really know if

you should be approaching your GLP-1

medications after learning all this

stuff, we offer a free discovery call

with our patient educators, where they

can help you think through your total

situation, what your journey is like,

and more importantly, what it's like to

work with me or my coaches so that we

can help structure a safe program, and

more importantly, one that gets you

results long-term. You can text the

number on the screen or check out the

link in the description if you want to

explore that. But first, let's go over

the numbers, because the numbers are

where the real picture comes together.

So, in the general population, estimates

range from about 1 to 10,000 to 1 in

50,000 adults per year. Now, that rate

climbs with age, and that's the

baseline. In adults on a GLP-1, one

major database study put that number

somewhere closer to 1 in 2,700 adults.

Of course, estimates are going to vary

across studies. Now, I think it's

important to talk about the fact that

partial blindness is such a debilitating

issue that if it happens to you or any

other loved one, there's an immediate

frame where the stats and the

probability of it actually happening

completely are just out of sight and all

of a sudden you're stuck on the fact

that this is going to happen everybody

else. But that's why I'm doing this

video because while it is awful and I'm

going to teach you guys how to minimize

your risk, I think it's important to

take a step back and realize that the

stats are the stats and that's the real

risk. And we're going to cover those two

as well so that you guys understand what

the real risk is versus what you might

think it is and where emotion might

impact that. It's also important to know

that this risk isn't evenly distributed

across time. So, early reports suggest

that NAION cases cluster in the window

when patients hit and sustain maximum

doses. For most patients on standard

titration schedules, that lands

somewhere in the first couple years on

the therapy. So, if you've been on a

GLP-1 for three, four, five years,

you're well past the window where most

of the documented cases appeared. You

are not accumulating risk the way that

the headlines make it sound like you

are. And not every GLP-1 shows the same

signal. Semaglutide, for example, is

where most of the current signal sits.

That's Ozempic and Wegovy. The data on

other GLP-1s is still emerging. Then

there's tirzepatide, Mounjaro and

Zepbound. It doesn't show the same

signal yet, though it's only been on the

market for a couple years. So, it's too

early to say definitively. And with

semaglutide, there's one pattern that

stands out. Early reports suggest

Wegovy, the higher dose weight loss

version, shows a stronger signal than

the lower dose version, Ozempic. The

exact magnitude, though, is still being

sorted out. Now, that's a dose story and

we're going to come back to that in a

minute because that's crucial and that's

how I'm going to teach you how to

minimize your risk. Now, we have to talk

about the other side of the ledger here.

What these medications are actually

preventing because that's the number

that you have to weigh this against.

Okay, so let's start with comparing the

risks and what you're going to lose if

you stop the medication, right? Because

there's a benefit to being on these

medications that I'm arguing is

significantly more than this. I want us

to get into this. One

in 2,700 cases, which is the worst of of

what we said, but I'm going to go ahead

and give that to you. But then, this is

crucial because we know heart attack

risk decreases, stroke risk decreases,

deaths, mortality, flat out, they're

prevented. So, let me map this out. On

one side of the ledger, we have a risk

of one in 2,700 shot of getting this

condition. The other side, what these

medications are actually preventing, and

this column is bigger for a reason. The

SELECT trials looked at semaglutide in

adults with obesity and cardiovascular

risk. A 20% reduction in heart attacks,

strokes, and cardiovascular death. A

broader meta-analysis in people with

obesity without diabetes found roughly a

20% reduction in major cardiovascular

events. So, you're not comparing drug

risk to zero risk. You're comparing a

small, clustered, anatomy-dependent risk

of this condition, and AION, against a

well-documented reduction in the things

that actually kill most adults. And the

condition that these drugs are treating,

insulin resistance, type 2 diabetes,

obesity, is itself the leading cause of

blindness. That untreated disease has

its own eye problems. That's what

actually changes if you stop. The ledger

leans hard in the other direction. Now,

by the way, real quick, if that reframe

just landed, do me a solid and hit that

subscribe button because we put out two

GLP-1 videos every single week with the

same calibrated approach. No

fear-mongering, no cheerleading, just

the actual math on what works and what's

worth your attention, and be sure to hit

that bell. Okay, so what actually falls

into that one in 2,700? So, number one,

we have the disc at risk anatomy, the

crowded tunnel setup that we talked

about earlier. Your eye doctor can check

for this. Number two, existing eye

conditions, glaucoma, prior optic nerve

injury, anything that's already stressed

that nerve may add vulnerability. Number

three, age over 50 with high blood

pressure, diabetes, or sleep apnea.

Those conditions all affect small blood

vessel flow, including the blood flow to

your optic nerve. Number four, the

window when you hit and sustain maximum

dose. Remember that's almost always in

the first one to two years. Number five,

and this is where things get

interesting. The dose that you're on and

how fast you got there. The on-label

GLP-1 titration schedule is designed to

escalate patients to maximum dose in

about four to five months, though many

clinicians adjust that in practice,

which means under the standard protocol,

the peak exposure lands early and it

stays there. That's when the NAION

signal is the hottest. The protocol

itself is part of the risk profile. It's

the dose escalation trap, automatic

titration that pushes you up the dose

ladder without asking whether you

actually need to keep climbing. So,

here's the part that matters most. You

don't need maximum dose to lose weight.

And in our clinic, the patients who I

coach through GLP-1 therapy, they rarely

go above 0.75 to 1 mg of semaglutide,

5/7.5 mg of tirzepatide, or maybe four

or five of Rybelsus. Not because those

high doses are inherently bad. There are

people that need them, because most of

our patients are already hitting their

goals on lower doses because we're

implementing strategic lifestyle

interventions. You see, there's a window

where the medication is doing its job.

And above that window, you're paying the

exposure cost without much more benefit.

That's the therapeutic window and the

sweet spot in action. Across the

thousands of patients we've coached on

this lowest effective dose approach,

tracked over years with baseline exams

and symptom monitoring, we haven't seen

a single case. Now, that's

observational. The NAION condition

itself is rare enough that a single

clinic's zero case record isn't proof of

protection, but it's certainly

consistent with what the exposure math

would actually predict. Okay, the simple

version here. The standard protocol is

the risk profile. The lowest effective

dose is the mitigation. Quick minute, I

want to tell you guys about the Flow

Academy membership. Essentially, this is

my private community on Mighty Networks.

You'll have access to a community coach,

live coaching calls that I do, which are

unsolicited. I don't have to market like

my free lives. I'm just there to help

you guys out as much as possible and a

ton of free resources as well to guide

you through the various protocols that I

talk about in these videos. So, all you

got to do if you're interested in

joining that is just become a member to

this YouTube page and then there's a

link that you can access after you

become a member that will allow you to

join the community. Now, back to the

video. Now, if you want a full video on

exactly how we run the lowest effective

dose protocol, the dosing math, how we

time titration, why most patients never

escalate to the max, let me know in the

comments if that would be helpful to

you. Okay, so what do you actually do

with all of this? First up, know the red

flag symptoms. Sudden vision change in

one eye is the one to pay attention to.

A section of your visual field going

blank or gray. Some patients describe it

as seeing the outline of a shape like a

cupcake shape instead of the whole

image. Colors looking washed out in one

eye but not the other. These are not

wait-and-see symptoms. These are call

your eye doctor today symptoms. Evaluate

as soon as possible, ideally the same

day. Number two, three questions to ask

your eye doctor. Number one, can you do

a baseline dilated exam and document

whether you have a disc at risk anatomy

situation? That tells you which camp

you're in. Number two, if I develop any

symptoms, can you do an OCT, an optical

coherence tomography of my optic nerve?

That's the key imaging tool if something

changes, usually combined with a dilated

exam and visual field testing. And then

number three, given my condition and my

other conditions and what you see on my

exam, what's your honest read at my

risk? Now, many of you have told me that

your eye doctor was more worried than

your prescriber or the other way around.

You deserve a real answer from someone

who's looked at your actual eye. And

speaking of that disconnect, if you've

had that experience, let me know in the

comments when your eye doctor is more

worried than your prescriber or the

other way around because other people

reading this will know that they're not

alone in this. And now the hardest move,

the one a lot of you are considering

that I'd actually push back on. Don't

stop the medication cold turkey. I know

that sounds counterintuitive after

everything that we've just covered.

Think about the ledger here for a

second. Okay, so this is important.

And I've already mentioned it, but

we have weight regain

plus the metabolic

rebound.

Stopping suddenly can cost you the

cardiovascular protection. And that

benefit depends on staying on the

treatment. It sets up metabolic rebound.

Your appetite that comes roaring back.

And many patients regain a substantial

amount of the weight over the following

year. And I know a lot of you are

thinking right now, okay, if I shouldn't

stop cold turkey, then how do I

eventually taper off safely? That's a

whole separate video. If you want me to

make that video, let me know in the

comments and I'll film the whole

protocol, the dose step downs, the

timing, how to avoid weight regain, the

whole thing. Okay, so if you are going

to stop or switch, do it with your

prescriber and your eye doctor working

together, not as a solo decision after a

little Tik Tok video. Even the

Neuro-Ophthalmology Society that studies

this condition has put out a statement,

do not discontinue GLP-1s based on NAION

fear alone. The first 6 to 12 months on

a GLP-1 is also the foundation window. A

powerful stretch when your appetite and

eating patterns can reset and new habits

have a chance to lock in. And when your

relationship with food can reorganize.

It overlaps the window where NAION cases

cluster. Stopping inside it doesn't just

expose you to cardiovascular rebound, it

wastes the biggest opportunity that

these medications give you. Okay, so

this is what you're starting to

hopefully think with.

Max dose

equals higher

risk. Now, we can just ignore that cuz

we don't do the highest risk here, but

what we do do

lower

dose

lower risk.

And I would argue almost non-

existent. So, we also have the weight

regain

plus

the metabolic

rebound. Okay, so the move isn't

stopping. The move is navigating with

the right dose, the right monitoring,

and the right team. Now, before we wrap

up, where do you actually land on all

this? Because if everything that I just

covered made you realize that what you

actually need is that team, not a script

and ship prescriber, not a Google search

at 2:00 a.m., we offer free discovery

calls with our patient educators.

They're going to hear you out on your

history, what you've tried, and what's

on your mind going forward. You'll get a

feel for working with me, the coaches,

and our medical team. Then they're going

to walk through programs and pricing so

that you can picture what a supervised

year actually looks like. You can text

them on the screen or check out the link

in the description if you want to book

that. Another important thing that many

GLP-1 users get wrong is how to maximize

their results simply by injecting. So,

check out that video right there where I

break down what the research says of how

to actually approach injecting in a way

to maximize results. It's a super easy

lever to pull on, so take advantage of

that. We'll see you later.